Aclovate (alclometasone dipropionate) cream
Aclovate (alclometasone dipropionate) ointment
ACLOVATE Cream and Ointment contain alclometasone dipropionate (7(alpha)-chloro-11(beta),17,21-trihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate), a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
ACLOVATE Cream and Ointment are low to medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ACLOVATE Cream and Ointment may be used in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established (see PRECAUTIONS: Pediatric Use). Since the safety and efficacy of ACLOVATE Cream and Ointment have not been established in pediatric patients below 1 year of age, their use in this age-group is not recommended.
Published Studies Related to Aclovate (Alclometasone)
[Alclometasone dipropionate (Legederm) for the treatment of steroid-sensitive dermatoses in the elderly] [1990.06]
This is a randomized single blind parallel comparison of alclometasone dipropionate cream 0.1% vs hydrocortisone butyrrate in 39 geriatric patients (greater than 60 years old) with steroid sensible skin diseases. The regimen consisted of dosing patients with two applications of the two drugs every day for 4 weeks.
Metabolic fate of alclometasone dipropionate in rats, rabbits, and mice. Metabolic products and pathway following subcutaneous administration. [1990.07]
The metabolic fate of alclometasone dipropionate (ADP or S-3460) has been studied in rats, rabbits, and mice, with consideration of their interspecies differences. Several reference compounds related to ADP were synthesized for the determination and identification of the metabolites.This M-1 was a main metabolite in plasma of animals studied, and due to its relatively longer life time in the media, it seemed to allow a variety of metabolism to occur, giving the oxidative and conjugative metabolites mentioned above.
Clinical Trials Related to Aclovate (Alclometasone)
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO [Recruiting]
To assess the impact of prophylactic treatment on the incidence of adverse events in
advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single
agent. To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the
incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation
(HER-1 mutation, HER-2 mutation or HER-2 amplification).
Page last updated: 2006-01-31